Business Context and Reporting Period
QuidelOrtho Corp (QDEL) filed a Form 8-K on August 21, 2025, reporting the entry into a new material definitive Credit Agreement. The transaction was executed to refinance the company's previous credit agreement dated May 27, 2022.
Key Financial Metrics and Debt Structure
The new Financing package totals $3.4 billion, consisting of the following facilities:
- Term Loan A: $1.15 billion senior secured facility.
- Delayed Draw Term Loan A (DDTL): $100.0 million senior secured facility.
- Term Loan B: $1.45 billion senior secured facility.
- Revolving Credit Facility: $700.0 million.
On the closing date, the Company borrowed the full amounts of the Term Loan A and Term Loan B. Proceeds were used to repay the prior credit agreement (including principal, accrued interest, and fees) and to cover transaction expenses.
Interest Rates and Fees:
- Term Loan A & Revolver: Initial applicable rate of 2.25% per annum over Term SOFR (or 1.25% over Base Rate), subject to a pricing grid ranging from 1.75% to 2.50% (SOFR) based on leverage.
- Term Loan B: Fixed applicable rate of 4.00% per annum over Term SOFR (or 3.00% over Base Rate).
- Commitment Fee: 0.20% to 0.35% per annum on the unused portion of the Revolving Credit Facility.
Maturities: Term Loan A and Revolver mature on August 21, 2030; Term Loan B matures on August 21, 2032.
Material Changes Versus Prior Period
The primary material change is the termination of the May 27, 2022 credit agreement and its replacement with the new 2025 Credit Agreement. The new agreement introduces specific financial covenants not detailed in the prior filing text provided:
- Consolidated Leverage Ratio: Maximum of 4.50 to 1.00 for the first three fiscal quarters post-closing, reducing to 4.25 to 1.00 thereafter.
- Consolidated Interest Coverage Ratio: Minimum of 3.00 to 1.00.
The filing does not provide specific revenue, profit, or cash flow figures for the current or prior periods, as this is a transactional report rather than a periodic financial statement.
Guidance, Risks, and Covenants
Covenants and Restrictions: The agreement includes customary affirmative and negative covenants limiting asset sales, mergers, additional indebtedness, liens, investments, and affiliate transactions. Prepayment is required using Net Cash Proceeds from property dispositions or certain non-ordinary course receipts (e.g., insurance proceeds) if not reinvested.
Risks and Contingencies: Events of default include non-payment, covenant breaches, cross-defaults to other material indebtedness, bankruptcy, and change of control. An event of default could trigger acceleration of obligations.
Management Commentary: The filing references a press release (Exhibit 99.1) for further details but does not contain direct management commentary on future outlook or operational guidance within the text provided.
Key Facts for Investor Verification
- Verify the exact amount of cash on hand used alongside the new debt to repay the prior facility.
- Confirm the Company's current Consolidated Leverage Ratio to ensure compliance with the new 4.50 to 1.00 covenant threshold.
- Review the specific amortization schedule for the Term Loans commencing December 28, 2025.
- Assess the impact of the higher interest rate on Term Loan B (4.00% over SOFR) on future interest expense.
- Check for any cross-default provisions that might link this agreement to other existing material indebtedness.